EFC1580 BOREAS: A randomized double blind placebo controlled parallel group 52wk study to assess the efficacy, safety, and tolerability of Dupilumab in patients with moderate to severe COPD w/Type 2
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Sanofi US
Start Date
June 19, 2019
End Date
February 23, 2024
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Sanofi US
Start Date
June 19, 2019
End Date
February 23, 2024